Trials
4 active
10 in total · 6 in the EU
What this is
- How it works
- Lp(a) antisense oligonucleotide
- How it’s given
- “Pelacarsen will be provided as solution for injection in prefilled syringe 80 mg for subcutaneous injection.”In the company’s words, NCT06813911 on ClinicalTrials.gov
- Tested for
- Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Disease and Lipoprotein(a), Atherosclerotic Cardiovascular Disease, Aortic Stenosis
- Main trialPhase 3
- “The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”In the company’s words, NCT06813911 on ClinicalTrials.gov
- Other names
- TQJ230 · ISIS 681257
Other drugs for Atherosclerotic Cardiovascular Disease (ASCVD)
- ObicetrapibNewAmsterdam Pharma · Phase 3
- LaroprovstatAstraZeneca · Phase 3
- TemsirolimusMercator MedSystems, Inc. · Phase 3
- OlpasiranAmgen · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- OrforglipronEli Lilly · Phase 3
Coming up4
- 3 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- 9 Jan 2030Phase 3 trial completes · ClinicalTrials.gov
- 12 Mar 2030Phase 2 trial completes · ClinicalTrials.gov
- 8 Dec 2030Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 10 NovStatus changed: Active, not recruiting to Terminated · ClinicalTrials.gov NCT05900141
- 10 NovCompletion date moved: 2028-08-24 to 2026-10-15 · ClinicalTrials.gov NCT05900141
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 3 Feb 2028 | Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD | |
| Phase 3Active, not recruiting | 9 Jan 2030 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | |
| Phase 3Active, not recruiting | 8 Dec 2030 | Pelacarsen Roll-over Extension Program | |
| Phase 2Recruiting | 12 Mar 2030 | A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis | |
| Phase 3Completed | 28 Jan 2025 | A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany | |
| Phase 3Completed | 25 Mar 2026 | Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD | |
| Phase 3Completed | 16 Jul 2026 | Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD | |
| Phase 3Terminated | 15 Oct 2026 | An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | |
| Phase 3Withdrawn | 22 Jan 2029 | Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL | |
| Phase 1Completed | 19 Oct 2022 | Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026